Core Insights - Daré Bioscience has entered into an agreement with the Gates Foundation to receive up to approximately $499,000 for mentorship and project management support for research projects addressing preeclampsia, a significant unmet need in maternal care [1][2][3] Company Overview - Daré Bioscience is a biopharmaceutical company focused on women's health, aiming to bridge the gap between scientific innovation and practical solutions [1][5] - The company seeks to bring innovative, evidence-based solutions to market that address long-standing unmet needs in women's health, including areas such as contraception, sexual health, and menopause [5] Engagement Details - The engagement with the Gates Foundation will involve providing strategic mentorship and technical guidance to organizations conducting preclinical research on preeclampsia prevention, diagnosis, and treatment [2][3] - Preeclampsia is a leading cause of maternal and infant morbidity and mortality, with approximately 76,000 mothers and 500,000 babies dying from the condition each year [3][4] Strategic Alignment - This initiative aligns with Daré's long-term strategy to lead in women's health areas that have significant needs and limited treatment options [4][5] - The multi-year engagement aims to enhance the impact and sustainability of research funded through the Gates Foundation's Grand Challenges initiative [3][4]